Picture of 2Seventy Bio logo

TSVT 2Seventy Bio News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

2Seventy Bio Inc expected to post a loss of 17 cents a share - Earnings Preview

2Seventy Bio Inc TSVT.OQ TSVT.O is expected to show a rise in quarterly revenue when it reports  results on May 1 (estimated) for the period ending March 31 2025

The Cambridge Massachusetts-based  company is expected to report a 12.3% increase in revenue to $13.963 million from $12.44 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for 2Seventy Bio Inc is for a loss of 17 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 20.9% in the last three months. ​

Wall Street's median 12-month price target for 2Seventy Bio Inc is $5.00​, above​ its last closing price of $4.99. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDINGSTARMINESMARTESTIMATE®LSEG IBES ESTIMATEACTUALBEAT, MET, MISSEDSURPRISE %
Dec. 31 2024-0.20-0.26-0.37Missed-39.6
Sep. 30 2024-0.23-0.24-0.19Beat21.2
Jun. 30 2024-0.76-0.650.45Beat169.5​
Mar. 31 2024-0.79-0.81-1.01Missed-24.4
​​Dec. 31 2023-1.05-0.99-1.11Missed-12.1
Sep. 30 2023-1.20-1.03-1.00Beat2.8​
Jun. 30 2023-1.09-1.06-0.83Beat22.1
Mar. 31 2023-1.20-1.19-1.08Beat9.5
This summary was machine generated April 29 at 13:09 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on 2Seventy Bio

See all news